COPD or ACOS, should be encouraged to report any deterioration, for example, worsening of cough, wheezing and dyspnea, following initiation of LABA treatment to promote safety. A recent meta ...

The near-term pipeline for COPD has several ICS, LABA and LAMA combinations in development with claims of improved efficacy and better safety profiles. Moreover, the development of more innovative ...

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

Discover how moderate-to-vigorous physical activity can reduce exacerbations and corticosteroid use in COPD patients on dual ...

is more effective than a LABA combined with an inhaled corticosteroid (ICS) in moderate-to-severe COPD. In the study Spiolto - which combines tiotropium, the active ingredient in Boehringer's LAMA ...

Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.

In 2017, the FDA approved the removal of the boxed warning on all combination steroid/LABA inhalers. Taking higher doses of ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

The Spanish COPD guidelines recommend treatment of the ... to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more severe cases, theophylline or roflumilast may ...